IO Biotech (IOBT) Competitors $1.74 -0.03 (-1.69%) Closing price 04:00 PM EasternExtended Trading$1.75 +0.01 (+0.57%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IOBT vs. PRME, ARVN, ETON, SVRA, PVLA, ITOS, SNDL, CGEM, CMPS, and KODShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Prime Medicine (PRME), Arvinas (ARVN), Eton Pharmaceuticals (ETON), Savara (SVRA), Palvella Therapeutics (PVLA), iTeos Therapeutics (ITOS), SNDL (SNDL), Cullinan Therapeutics (CGEM), COMPASS Pathways (CMPS), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. Its Competitors Prime Medicine Arvinas Eton Pharmaceuticals Savara Palvella Therapeutics iTeos Therapeutics SNDL Cullinan Therapeutics COMPASS Pathways Kodiak Sciences IO Biotech (NASDAQ:IOBT) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has more risk & volatility, IOBT or PRME? IO Biotech has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Do insiders and institutionals have more ownership in IOBT or PRME? 54.8% of IO Biotech shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 4.8% of IO Biotech shares are held by company insiders. Comparatively, 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, IOBT or PRME? IO Biotech has higher earnings, but lower revenue than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$95.49M-$1.58-1.10Prime Medicine$4.96M96.30-$198.13M-$1.56-2.28 Does the media prefer IOBT or PRME? In the previous week, Prime Medicine had 5 more articles in the media than IO Biotech. MarketBeat recorded 8 mentions for Prime Medicine and 3 mentions for IO Biotech. IO Biotech's average media sentiment score of 0.68 beat Prime Medicine's score of 0.25 indicating that IO Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IO Biotech 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer IOBT or PRME? IO Biotech currently has a consensus target price of $8.67, suggesting a potential upside of 398.08%. Prime Medicine has a consensus target price of $8.92, suggesting a potential upside of 151.17%. Given IO Biotech's stronger consensus rating and higher possible upside, research analysts plainly believe IO Biotech is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Is IOBT or PRME more profitable? Prime Medicine's return on equity of -107.87% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -281.82% -169.29% Prime Medicine N/A -107.87%-74.97% SummaryPrime Medicine beats IO Biotech on 9 of the 14 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.86M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-1.1021.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book2.458.079.116.39Net Income-$95.49M-$54.72M$3.26B$265.66M7 Day Performance-19.44%2.62%2.11%1.98%1 Month Performance-10.77%7.63%5.12%1.33%1 Year Performance8.75%13.11%31.25%21.15% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.0933 of 5 stars$1.74-1.7%$8.67+398.1%+12.0%$123.86MN/A-1.1030PRMEPrime Medicine2.9212 of 5 stars$3.51-7.4%$8.92+154.0%-26.8%$472.08M$4.96M-1.71234Gap UpARVNArvinas4.109 of 5 stars$6.59+4.8%$19.76+199.9%-71.0%$461.80M$263.40M-6.52420Positive NewsETONEton Pharmaceuticals2.4496 of 5 stars$17.05-0.5%$29.67+74.0%+312.8%$459.65M$39.01M-106.5620Positive NewsInsider TradeSVRASavara3.3596 of 5 stars$2.70+2.3%$5.60+107.4%-31.9%$456.29MN/A-5.6220PVLAPalvella Therapeutics1.9697 of 5 stars$41.71+2.0%$52.40+25.6%N/A$452.18M$42.81M-3.45N/ANews CoverageAnalyst ForecastITOSiTeos Therapeutics2.4092 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M-2.1690Positive NewsSNDLSNDL1.8281 of 5 stars$2.01+19.3%$4.00+99.5%+6.2%$441.46M$671.81M-7.432,516High Trading VolumeCGEMCullinan Therapeutics1.7856 of 5 stars$7.09-2.9%$30.00+323.1%-57.4%$430.95MN/A-2.2030News CoverageAnalyst ForecastAnalyst RevisionCMPSCOMPASS Pathways2.6396 of 5 stars$4.34-1.1%$16.29+275.2%-38.8%$421.18MN/A-2.36120KODKodiak Sciences3.2361 of 5 stars$8.03+1.6%$9.00+12.1%+248.0%$416.83MN/A-2.2190Analyst Revision Related Companies and Tools Related Companies Prime Medicine Competitors Arvinas Competitors Eton Pharmaceuticals Competitors Savara Competitors Palvella Therapeutics Competitors iTeos Therapeutics Competitors SNDL Competitors Cullinan Therapeutics Competitors COMPASS Pathways Competitors Kodiak Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOBT) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access